Phase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration-resistant prostate cancer

OBJECTIVE: To determine the safety and clinical efficacy of two anti-angiogenic agents, bevacizumab and lenalidomide, with docetaxel and prednisone. PATIENTS AND METHODS: Eligible patients with metastatic castration-resistant prostate cancer enrolled in this open-label, phase II study of lenalidomid...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:BJU Int
Asıl Yazarlar: Madan, Ravi A., Karzai, Fatima H., Ning, Yang-Min, Adesunloye, Bamidele A., Huang, Xuan, Harold, Nancy, Couvillon, Anna, Chun, Guinevere, Cordes, Lisa, Sissung, Tristan, Beedie, Shaunna L., Dawson, Nancy A., Theoret, Marc R., McLeod, David G., Rosner, Inger, Trepel, Jane B., Lee, Min-Jung, Tomita, Yusuke, Lee, Sunmin, Chen, Clara, Steinberg, Seth M., Arlen, Philip M., Gulley, James L., Figg, William D., Dahut, William L.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2016
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6387685/
https://ncbi.nlm.nih.gov/pubmed/26780387
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bju.13412
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller